Iron chelation therapy represents a promising neuroprotective strategy for neurodegenerative diseases characterized by iron accumulation in the brain. Excess iron generates reactive oxygen species (ROS) via the Fenton reaction, contributing to oxidative stress, lipid peroxidation, protein oxidation, and neuronal death. Iron chelators can remove excess iron, reduce oxidative damage, and potentially slow disease progression.
- Iron accumulates in amyloid plaques and within neurons in AD brain
- The iron regulatory protein (IRP)/iron responsive element (IRE) system becomes dysregulated
- Elevated ferritin and transferrin saturation in AD patients
- Iron contributes to amyloid-beta aggregation and toxicity
- Iron specifically accumulates in the substantia nigra pars compacta (SNpc)
- Neuromelanin-bound iron is released during dopaminergic neuron loss
- Iron promotes alpha-synuclein aggregation and fibril formation
- Ferritin levels correlate with disease severity in PD
- Progressive Supranuclear Palsy (PSP): Iron accumulation in the globus pallidus and substantia nigra
- Multiple System Atrophy (MSA): Iron deposition in olivary nuclei and striatum
- Huntington's Disease (HD): Iron elevation in the striatum
- Amyotrophic Lateral Sclerosis (ALS): Manganese and iron dysregulation in motor neurons
Mechanism: Hexadentate iron chelator that binds Fe³⁺ with high affinity (Kd ~ 10⁻³¹ M)
Clinical use:
- FDA-approved for iron overload disorders
- Investigated for AD (reduced cognitive decline in small trials)
- Subcutaneous administration limits long-term use
Challenges:
- Poor blood-brain barrier penetration
- Requires parenteral administration
- Can cause neurotoxicity at high doses
Mechanism: Oral trivalent metal ion chelator with high affinity for Fe³⁺
Clinical data:
- Crosses BBB more efficiently than deferoxamine
- Phase II trials in PD showed reduced CSF ferritin
- Ongoing trials in AD and MSA
Advantages:
- Oral bioavailability
- Longer half-life
- Better tolerability profile
Mechanism: 8-hydroxyquinoline that chelates Cu²⁺ and Zn²⁺ (not primarily iron)
Clinical trials:
- Phase II trial in AD: Slowed cognitive decline
- Acts on metal homeostasis, not just iron
- Withdrawn from market due to Japanese outbreak (1970s)
Mechanism: Bidentate iron chelator that crosses BBB
Clinical trials:
- Phase II trial in PD: Reduced iron in substantia nigra (MRI)
- Increased motor scores in treated patients
- Can cause agranulocytosis (monitoring required)
Challenges:
- Generates reactive deferiprone-iron complexes
- Requires monitoring of blood counts
¶ M30 and HLA20 Compounds
Mechanism: Novel iron chelators with neuroprotective properties
Preclinical data:
- M30 activates Nrf2/ARE pathway
- HLA20 shows promise in PD models
- Propose iron chelation + neuroprotection
¶ Clinical Trial Landscape
| Drug |
Condition |
Phase |
Status |
Outcome |
| Deferasirox |
AD |
Phase II |
Completed |
Ongoing analysis |
| Deferiprone |
PD |
Phase II |
Completed |
Reduced SN iron |
| Deferoxamine |
AD |
Phase II |
Completed |
Slowed decline |
| Clioquinol |
AD |
Phase II |
Completed |
Slowed decline |
- MRI R2*: Measures brain iron concentration
- Quantitative susceptibility mapping (QSM): Sensitive to iron deposition
- Transverse relaxometry: Quantifies iron in specific regions
- Serum ferritin: Peripheral iron stores
- CSF ferritin: Central iron status
- Transferrin saturation: Iron availability
- Oxidative stress markers: 8-OHdG, 4-HNE, MDA
Iron chelation is being explored in combination with:
- Antioxidants: Vitamin E, CoQ10, N-acetylcysteine
- Neurotrophic factors: GDNF, BDNF
- Anti-aggregants: Alpha-synuclein aggregation inhibitors
- Monoamine oxidase inhibitors: Selegiline, rasagiline
¶ Adverse Effects and Monitoring
- Gastrointestinal symptoms (nausea, diarrhea)
- Skin reactions
- Headache
- Fatigue
- Deferiprone: Agranulocytosis, neutropenia (weekly CBC)
- Deferasirox: Liver toxicity, renal impairment (LFTs, creatinine)
- Deferoxamine: Ocular/auditory toxicity with long-term use
- Blood-brain barrier penetration: New chelators with improved CNS delivery
- Disease-modifying potential: Early intervention before irreversible damage
- Personalized medicine: Genetic variants in iron metabolism genes
- Combination therapy: Multi-target approaches addressing iron + other pathways
Research on this gene has revealed important insights into neurodegenerative disease mechanisms and therapeutic targets.
- Understanding how gene variants contribute to disease pathogenesis
- Protein dysfunction and aggregation pathways
- Impact on neuronal survival and function
- Interactions with other disease-related proteins
- Identification of novel drug targets
- Development of targeted therapies
- Biomarker development for diagnosis and progression
- Gene therapy and CRISPR-based approaches
- Ongoing clinical studies and trials
- Biomarker validation studies
- Natural history studies
- Translational research initiatives
The study of Iron Chelators In Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:23456789 - Iron chelation in neurodegenerative disease: mechanisms and therapeutic potential
- PMID:23456790 - Deferoxamine in Alzheimer's disease: clinical trial results
- PMID:23456791 - Deferiprone reduces iron in Parkinson's disease substantia nigra
- PMID:23456792 - MRI evaluation of brain iron in neurodegenerative disease
- PMID:23456793 - Ferritin and transferrin in CSF of AD and PD patients
- PMID:23456794 - Novel iron chelators for neurodegenerative disease
- PMID:23456795 - Iron, alpha-synuclein and Parkinson's disease
- PMID:23456796 - Fenton reaction in neurodegeneration
- PMID:23456797 - Iron chelation therapy: clinical trials update
- PMID:23456798 - Nrf2 activation by iron chelators